<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04937712</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00724-37</org_study_id>
    <nct_id>NCT04937712</nct_id>
  </id_info>
  <brief_title>Analysis of SARS-CoV2 Urine Viral Particles and Association With Proximal Tubular Dysfunction</brief_title>
  <acronym>CovUrinePTD</acronym>
  <official_title>Molecular Characterization and Cellular Infection Capacity of Urinary Viral Particles Isolated From SARS-CoV-2 and Association With Proximal Tubular Dysfunction, in Hospitalized Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal is to detect Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2)&#xD;
      urine viral particles in patients in intensive care units, hospitalized for coronavirus&#xD;
      Coronavirus Disease-19 (COVID-19) infection, and correlate the presence of the virus in the&#xD;
      urine with proximal tubular dysfunction (defined by the association of at least 2&#xD;
      abnormalities: tubular proteinuria, renal phosphate leak, uricosuria, normoglycemic&#xD;
      glycosuria, amino aciduria)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>SARS-CoV 2 viruria and its correlation with proximal tubule dysfunction</measure>
    <time_frame>During the first 10 days of hospitalization</time_frame>
    <description>Is the detection of viral particles in urine associated with proximal tubule dysfunction, defined by two or more of the following : proteinuria, phosphate leak, aminoaciduria, hyperuricuria, and/or glycosuria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Capacity of infection of urine viral particles</measure>
    <time_frame>During the first 10 days of hospitalization</time_frame>
    <description>Study of the capacity for cell infection in vitro by viral particles detected in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sequencing viral particles to identify possible compartmentalization of the virus</measure>
    <time_frame>During the first 10 days of hospitalization</time_frame>
    <description>Study by sequencing of the compartmentalization of urinary and nasopharyngeal variants of SARS-CoV-2 in patients with positive urine for SARS-CoV-2.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">34</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <condition>Proximal Tubule Dysfunction</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RT-PCR SARS-COV2 in urine</intervention_name>
    <description>proteinuria/renal phosphate leak/uricosuria/glycosuria/ aminoaciduria)</description>
    <other_name>Proximal tubular dysfunction testing</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Reverse Transcriptase -Polymerase Chain Reaction (RT-PCR) for SARS-CoV2 in urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalized in CHRU Nancy with severe SARS-CoV2 infection, with lung involvement.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Person and / or trustworthy person who has received complete information on the&#xD;
             organization of the research and who has not opposed their participation and the use&#xD;
             of their data&#xD;
&#xD;
          -  Hospitalized for ≥ 48 hours and ≤ 10 days&#xD;
&#xD;
          -  SARS-CoV-2 positive nasopharyngeal sample&#xD;
&#xD;
          -  Severity criteria: Lung involvement described as compatible with SARS-CoV-2 on&#xD;
             radiography or scanner and partial pressure of oxygne (PaO2) / Fraction of inspired&#xD;
             oxygen (FiO2) ≤ 300 mmHg and / or respiratory rate (RR) ≥ 30 / min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known chronic kidney disease, or initial Glomerular Filtration Rate (GFR) &lt;60 ml / min&#xD;
             / 1.73m2 or Renal Transplant&#xD;
&#xD;
          -  Known proteinuria&#xD;
&#xD;
          -  Known proximal tubulopathy&#xD;
&#xD;
          -  Treatment with Forxiga&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Raphaël Kormann</last_name>
    <phone>+33383155533</phone>
    <email>r.kormann@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chru Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaël Kormann, MD PhD</last_name>
      <phone>0033383155533</phone>
      <email>r.kormann@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kormann R, Jacquot A, Alla A, Corbel A, Koszutski M, Voirin P, Garcia Parrilla M, Bevilacqua S, Schvoerer E, Gueant JL, Namour F, Levy B, Frimat L, Oussalah A. Coronavirus disease 2019: acute Fanconi syndrome precedes acute kidney injury. Clin Kidney J. 2020 Jun 8;13(3):362-370. doi: 10.1093/ckj/sfaa109. eCollection 2020 Jun.</citation>
    <PMID>32695327</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>June 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 24, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Raphaël KORMANN</investigator_full_name>
    <investigator_title>Principal investigator, Medical Doctor, Nephrologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

